8-K: AVITA Medical Secures $60M Credit, Boosts 2026 Outlook

AVITA Medical refinanced its debt with a new $60 million credit facility from Perceptive Advisors and provided an update on its 2025 revenue and 2026 guidance.

Summary

• AVITA Medical, Inc. (RCEL) entered into a new five-year senior secured credit facility of up to $60 million with Perceptive Credit Holdings V, LP.
• An initial $50 million was funded on January 13, 2026, with an option to draw an additional $10 million through March 31, 2027, subject to a net revenue requirement.
• The proceeds were used to repay in full and terminate obligations under the existing credit agreement with OrbiMed Advisors, LLC.
• Interest on outstanding amounts will accrue at a rate per annum equal to the greater of (x) the SOFR rate for such period and (y) 4.00% plus, in either case, 7.50%.
• A warrant certificate was issued to Perceptive Credit Holdings V, LP, entitling them to purchase up to 650,000 shares of the company's common stock.
• The initial 500,000 warrant shares are exercisable at $3.4019, with an additional 150,000 shares vesting if the Tranche B Term Loan is funded.
• The warrant has a term of 10 years from its issuance date and includes customary share adjustment provisions and weighted average price protection.
• The company reported unaudited preliminary total net revenues of approximately $17.6 million for Q4 2025, compared to $18.4 million in Q4 2024.
• Unaudited preliminary total revenues for full year 2025 were approximately $71.6 million, an 11% increase from $64.3 million in FY 2024, meeting the company's revised guidance.
• Full year 2026 revenue is expected to be in the range of approximately $80 million to $85 million, representing growth of approximately 12% to 19% compared to 2025 revenue.
• The Cohealyx-I study was fully enrolled, and the PermeaDerm-I study surpassed 75% enrollment in December 2025, with data from both expected later in 2026.

Sentiment

Score: 7

Explanation: The company secured significant financing, refinanced existing debt, and provided positive revenue guidance for 2026, indicating a strengthened financial position and clear growth path. While Q4 2025 revenue was slightly down year-over-year, the overall FY2025 growth met revised guidance, and clinical milestones are progressing. The risks associated with warrant approval and covenants are noted but appear manageable based on management's comments.

Positives

• Secured a new five-year senior secured credit facility of up to $60 million, strengthening the company's capital structure and supporting long-term growth.
• Successfully refinanced existing debt, improving financial flexibility and terminating prior obligations.
• Achieved 11% revenue growth for full year 2025, reaching $71.6 million, which was within the company's revised guidance.
• Provided positive full year 2026 revenue guidance of $80 million to $85 million, indicating anticipated growth of 12% to 19%.
• Advanced clinical pipeline with Cohealyx-I study fully enrolled and PermeaDerm-I study surpassing 75% enrollment, with data expected later in 2026.
• Management believes the new trailing twelve-month (TTM) revenue covenants are 'appropriate and manageable' based on operating performance and forward outlook.
• Partnering with Perceptive Advisors, a healthcare-focused investment firm, brings deep industry expertise and a collaborative approach.

Negatives

• Preliminary Q4 2025 net revenues of approximately $17.6 million were lower than Q4 2024 revenues of $18.4 million.
• The issuance of a warrant certificate for up to 650,000 shares of common stock to Perceptive Credit Holdings V, LP could lead to dilution for existing shareholders upon exercise.
• A 5% exit fee will be incurred if shareholder approval for the warrant issuance is not secured by September 30, 2026.
• Prepayment premiums ranging from 1% to 10% of the prepaid amount apply to any voluntary or mandatory prepayments of the loan facility.
• The credit agreement contains customary events of default and restrictive covenants, including financial maintenance tests, which could limit operational flexibility.

Risks

• Failure to obtain shareholder approval for the issuance of the warrant by September 30, 2026, will result in an exit fee equal to 5% of the aggregate principal amount borrowed.
• Failure to obtain shareholder approval for the issuance of the warrant by November 30, 2026, will constitute an Event of Default under the Credit Agreement.
• Risk of not meeting the specified minimum net revenue financial covenants, such as $68.5 million for the trailing twelve-month period ending March 31, 2026, and $73 million for the full year 2026.
• Risk of not maintaining at least $5 million of unrestricted cash at all times, as required by the Credit Agreement.
• The company's forward-looking statements, including revenue guidance and timing of clinical trial data, are subject to significant risks and uncertainties that could cause actual results to differ materially.
• Risks associated with international operations and expansion, as well as other economic or political conditions outside of the company's control, could impact performance.

Future Outlook

AVITA Medical expects full year 2026 revenue in the range of $80 million to $85 million, representing growth of approximately 12% to 19% compared to 2025. The company anticipates data from the Cohealyx-I and PermeaDerm-I clinical studies later in 2026, positioning for 'execution-led growth and deliver more predictable, scaled performance.'

Management Comments

• "Over the past year, we have focused on strengthening the foundation of the business – stabilizing revenue, advancing our clinical pipeline, and improving financial flexibility." Cary Vance, Interim Chief Executive Officer of AVITA Medical.
• "With a strengthened balance sheet and key clinical and commercial milestones ahead, we enter 2026 positioned to shift from stabilization to execution-led growth and deliver more predictable, scaled performance." Cary Vance, Interim Chief Executive Officer of AVITA Medical.
• "This financing represents an important step in strengthening AVITA Medicals capital structure while preserving shareholder value, including a reset of our revenue covenants to levels we believe are appropriate and manageable based on our operating performance and forward outlook." David OToole, Chief Financial Officer of AVITA Medical.
• "We are pleased to partner with Perceptive Advisors, whose deep healthcare expertise and collaborative approach align well with our commitment to building a durable, growth-oriented business and our long-term vision." David OToole, Chief Financial Officer of AVITA Medical.
• "AVITA Medical has established a differentiated position in acute wound care with a clear path to value creation through both commercial execution and clinical advancement." Sam Chawla, Portfolio Manager at Perceptive Advisors.
• "With multiple near-term catalysts, we believe the Company is well positioned to scale efficiently and progress toward sustainable profitability, and we are pleased to support the management team through this next phase of growth." Sam Chawla, Portfolio Manager at Perceptive Advisors.

Industry Context

The company operates in the therapeutic acute wound care market, focusing on solutions like the RECELL System, PermeaDerm, and Cohealyx. The financing from a healthcare-focused investment firm like Perceptive Advisors suggests confidence in the sector and AVITA Medical's differentiated position. The focus on clinical advancement and commercial execution aligns with broader trends in medical device and biotech for growth through innovation and market penetration.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks for direct assessment against industry standards.

Corporate Governance

Related Party Transactions

• The company entered into a Credit Agreement and Guaranty with Perceptive Credit Holdings V, LP, and issued a warrant certificate to them. Perceptive Credit Holdings V, LP is a healthcare-focused investment firm and the lender/administrative agent in this transaction.

Stakeholder Impact

• Shareholders: Potential dilution from the exercise of warrants, but also benefit from a strengthened capital structure, improved financial flexibility, and positive revenue guidance for 2026, which could support long-term value creation.
• Creditors (Perceptive Advisors): Secured a senior credit facility with comprehensive financial covenants and warrants, providing a strong position and potential equity upside.
• Employees and Management: The financing supports continued operations, clinical advancement, and execution-led growth, providing stability and clear strategic direction.
• Customers: Continued development and commercialization of innovative wound care products like the RECELL System, PermeaDerm, and Cohealyx.

Next Steps

• AVITA Medical will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
• The company plans to report its financial results for the fourth quarter and full year 2025 on February 12, 2026.
• Data from the Cohealyx-I and PermeaDerm-I clinical studies are expected later in 2026.
• The company must seek shareholder approval for the warrant issuance by September 30, 2026, to avoid a 5% exit fee, and by November 30, 2026, to avoid an Event of Default.
• The company has the option to draw an additional $10 million Tranche B Term Loan through March 31, 2027, subject to meeting a net revenue requirement.
• The company is required to file a registration statement covering the resale of the warrant shares within 30 days of the warrant issuance date.

Key Dates

Recommendation

The new credit facility and debt refinancing provide a stable financial foundation and flexibility for AVITA Medical, addressing immediate capital needs. The 2026 revenue guidance indicates continued growth, and clinical milestones are progressing. However, the Q4 2025 revenue decline and the potential for shareholder dilution from the warrants, along with the strict financial covenants, introduce elements of caution. The stock is likely to react positively to the financing and outlook, but a 'hold' recommendation is appropriate until further clarity on sustained revenue growth and clinical trial outcomes is available, and the impact of dilution is fully absorbed.

Keywords

AVITA Medical, RCEL, credit facility, debt refinancing, Perceptive Advisors, warrant, revenue guidance, financial results, wound care, RECELL System, PermeaDerm, Cohealyx, clinical trials, SEC filing, 8-K